Serum immune checkpoint profiling identifies soluble CD40 as a biomarker for pancreatic cancer
Abstract Pancreatic ductal adenocarcinoma (PDAC) responds poorly to systemic treatment, including new immunotherapeutic approaches. Biomarkers are urgently needed for early disease detection, patient stratification for treatment, and response prediction. The role of soluble CD40 (sCD40) is unknown i...
保存先:
| 主要な著者: | , , , , , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Nature Portfolio
2023-10-01
|
| シリーズ: | npj Precision Oncology |
| オンライン･アクセス: | https://doi.org/10.1038/s41698-023-00459-9 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|